Trending Sources

Xconomy Special Report: 12 San Diego Tech Startup to Watch in 2017

Xconomy

View the Slideshow A little more than a year ago, amid a resurgence in San Diego’s software sector, Xconomy identified a baker’s dozen of local tech companies to watch in 2016. I started with a list of companies already screened by the San Diego Venture Group’s annual venture summit, and consulted with investors and startup mentors to refine the list.

San Diego Startups Raise $287M in Third Quarter, and Top 10 Deals

Xconomy

Venture Capital investments in San Diego startups fell by roughly a third during the three months that ended September 30, according to data released recently by Seattle-based PitchBook and the National Venture Capital Association. million in 49 startups in San Diego County during the third quarter, according to a breakout of data provided by PitchBook as part of the inaugural “Venture Monitor” report. San Diego. $35 San Diego. $20

Santa Barbara, San Diego Tops On Per-Capita Venture Capital

socalTECH

A new study released earlier this month has ranked the Santa Barbara-Santa Maria-Goleta metropolitan area, as well as the San Diego-Carlsbad-San Marcos metropolitan area among the top ten markets for venture capital activity. San Jose-Sunnyvale-Santa Clara; 2.

San Diego Innovation Economy Extended Gains in 2015: Connect Report

Xconomy

San Diego’s innovation clusters continued to grow in 2015, as local startups, funding deals, and job growth extended an economic growth spurt that began in 2013. Innovation Companies in San Diego (Courtesy Connect Innovation Report).

Q2 VC Funding Soars in San Diego (After Revisions), and Top 10 Deals

Xconomy

After the national MoneyTree Report was released last week, PricewaterhouseCoopers partner Ryan Spencer said he spent time on a call with Thomson Reuters, which provides the raw data, trying to figure out a change in the numbers for venture capital activity in San Diego.

Gottlieb Reportedly On Tap to Lead FDA, and Biopharma Exhales

Xconomy

According to several news reports, the Trump administration will nominate Scott Gottlieb to be the new commissioner of the FDA, a selection that had the life sciences industry breathing a sigh of relief Friday afternoon.

News 34

Synthetic Genomics Creates Host Organism Optimized for Bio Industry

Xconomy

Scientists from Synthetic Genomics, the San Diego-based industrial biotech, have re-engineered a fast-growing microorganism found in salt marsh mud to maximize its production of proteins and to optimize other common bio-based processes.

Avelas Bio Raises $20M to Push Cancer-Illuminating Biologic Agent

Xconomy

San Diego’s Avelas Biosciences , founded in 2009 to advance a fluorescing biologic agent intended to help surgeons differentiate cancerous tissue from healthy tissue, has completed a $20 million Series C round of venture funding. and San Diego’s Avalon Ventures.

Study 36

Dauntless Takes Flight with New Business Model for Starting Biotechs

Xconomy

First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. David Kabakoff, a Sofinnova partner in San Diego, also is a Dauntless board member.

Two San Diego Sites Rank Tops In Rising Social Networking Interest

socalTECH

A report issued this week by Experian Marketing Services has identified two, San Diego niche social networking sites as being among the fastest growing sites between July of 2011 and July of 2012.

San Diego Sees Strong Cybersecurity Growth As Firms Seek Talent

Xconomy

San Diego’s cybersecurity workforce has grown by nearly 15 percent over the past two years, according to a study released today by the Cyber Center of Excellence, a nonprofit industry group created to boost cybersecurity jobs and technologies in the region. The center commissioned the report to help quantify the economic impact of the cybersecurity industry in San Diego, and to assess how employers view their prospects for growth and needs for future hiring.

Sony Slashes Staff At San Diego Game Studio

socalTECH

Sony has cut more than 50 employees in San Diego, at its Sony San Diego Studio , which develops videogames such as Kill Strain and MLB. According to reports , the layoffs are part of a wider cut in its videogaming operations which also included workers in London. Gamasutra reported the moves are possibly a move away from "live games" development at Sony. sony diego studios videogame studio layoff jobs employment online games

At “The Vine,” Developer Builds a Vertical Campus for Tech Startups

Xconomy

In downtown San Diego, a private real estate company best known for its master-planned communities in suburban Southern California has posed some existential questions for regional tech hubs looking to build their own startup ecosystems. 101 West Broadway tower in downtown San Diego.

Immunotherapy Clinical Tests Spur Hope, and Plenty of Headaches

Xconomy

“A number of patients are sick and tired of chemo, so they’ll roll the dice, knowing they won’t stay on the study” if they are assigned to take chemo, says Andrew Ko, a gastrointestinal cancer specialist at the University of California, San Francisco.

Study 35

Nervana’s $400M+ Buyout Reflects Key Tech Trend in Machine Learning

Xconomy

On the day after Intel announced its acquisition of San Diego machine learning startup Nervana Systems, investor Steve Jurvetson told me he was feeling a sense of satisfaction about a call he made three years ago, and how it has been playing out.

ViaCyte Working with Gore to Improve its Synthetic Pancreas Device

Xconomy

San Diego-based ViaCyte said today it is collaborating with W.L. When ViaCyte reported preliminary results from its initial clinical.

Websense, After Move From San Diego, In Acquisition Talks

socalTECH

Former San Diego-based security software developer Websense > --one of a number of companies acquired by private equity investor Vista Equity Partners and moved out of San Diego--is now in talks to be acquired by Raytheon , according to a report. Bloomberg reports that the companies are in talks to sell Websense to Raytheon in a deal worth more than $1 billion.

14 for ’17: Key Clinical Data To Watch For Next Year (Part 2)

Xconomy

Editor’s note: Ben Fidler and Frank Vinluan contributed to this report.] We continue our look ahead to some of the clinical data due in 2017 that could shape healthcare practice and sway investor sentiment for years to come. Part one of our preview is here , with looks at key studies in lung cancer, Alzheimer’s disease, asthma, and more.

IBM Watson Health Launches Imaging Effort for Cancer, Other Diseases

Xconomy

Watson Health is teaming up with 16 partners, which include imaging and diagnostics company Hologic; Sentara Healthcare; Sheridan Healthcare; UC San Diego Health; University of Miami Health System; and Merge Healthcare, which was acquired by IBM last year and is now part of Watson Health.

IBM 36

New U.S. “Roadmap” Lays Out Routes to Accelerate Robotic Technologies

Xconomy

Christensen made his observations during a presentation at the 2016 Contextual Robotics Forum, a recent conference at UC San Diego focused this year on “new directions in human-machine interaction.”.

BlackThorn Emerges With $40M, New Weapons Against Neuro Disorders

Xconomy

As Xconomy reported last year, South San Francisco, CA-based BlackThorn was spun out of Scripps Research Institute , which on its website lists the company as one of its 2013 spinouts.

Study 29

All In One Place: A New Immuno-Oncology Trial Resource

Xconomy

As reporters, we find that frustrating. More than 100 years ago, New York bone surgeon William Coley began to suspect that bacterial infections might be improving the outlook for patients also suffering from cancer. The infections were turbo-charging the immune system.

New Data Show Biogen, Ionis Drug Might Help More With Rare Spine Disease

Xconomy

In August, Biogen and Ionis reported positive data from a trial in infants with type 1 SMA and, as with its news today, stopped that study so that patients could transition to an open-label extension study and get nusinersen.

Study 27

Biogen Buys Ionis Spine Disease Drug For $75M, Eyes FDA Filing

Xconomy

Ionis (NASDAQ: IONS ) and its partner, Cambridge, MA-based Biogen (NASDAQ: BIIB ), this morning reported an interim look at an ongoing Phase 3 study of nusinersen—an RNA-based drug meant to help treat patients with SMA. Spinal muscular atrophy affects over 25,000 people in the U.S.

Study 29

San Diego's Mapp Bio Behind Experimental Ebola Drug

socalTECH

A San Diego-based biopharmaceuticals startup, Mapp Biopharmaceuticals , is the source of the experimental Ebola treatment that has been given to the two Americans who are being treated for the dreaded disease, according to CNN. According to the report, Dr. Kent Brantly and Nancy Writebol, who were both in Liberia, have both been treated using the experimental, treatment, which had not yet been tested in humans, and have "significantly improved" due to the drug.

Texas Looks To Steal Away Another San Diego Company, Omnitracs

socalTECH

According to reports, Omnitracs is in the midst of negotations to move its operations out of San Diego, and to Austin, following the recent sale of Omnitracs by Qualcomm to private equity firm Vista Equity Partners. If the deal goes through, the company will be the second Vista Equity owned company in San Diego to move to Austin, after the move last week of computer security software WebSense --also owned by Vista Equity. texas diego omnitracs jobs employment

Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA

Xconomy

According to a 2015 report from EvaluatePharma , the market for drugs for rare, or “orphan” diseases, as they’re known, has been growing by 12 percent every year and is expected to reach $178 billion worldwide by 2020. Heather and Jessica Tomko will tell you that they’re nothing alike.

Biotech Roundup: Hellos, Goodbyes, “Cures” Delays And Trial News

Xconomy

Our San Diego editor Bruce Bigelow penned a personal goodbye to entrepreneur Larry Bock, who died last week of pancreatic cancer at the age of 56. Polaris Partners venture partner Amy Schulman is Lyndra’s CEO…San Francisco-based tissue analyzer 3Scan raised a $14 million Series B round from Lux Capital and Data Collective…and Magnolia Medical Technologies of Seattle, maker of a diagnostic tool for sepsis, rounded up nearly $14 million.

News 28

The Five Major Tech Trends of 2016

Xconomy

Back in 2013, Google reported that 90 percent of multiple device owners switch between screens to complete tasks, using an average of three different combinations every day.

Despite Low Crop Prices, Corporate and VC Agtech Investments Soar

Xconomy

Venture capital firms have increased their agtech investments by 80 percent since 2012, bringing total VC investment in the sector to a total of $3 billion in 2015, according to a new report from Boston Consulting Group and AgFunder, an online investment marketplace for agriculture technology.

Bio Roundup: Trump’s Rx Silence, PCSK9 News, Amgen’s Migraines & More

Xconomy

president’s intent to make good on his angry campaign rhetoric on drug prices, while the Associated Press reported that naming-and-shaming—that is, Congress hauling executives into hearings and penning angry letters—certainly hasn’t done the trick. Speculation swirled this week around the incoming U.S.

Press 19

Drug-Hunting Startup From Scripps Attracts Celgene Alum, $50M Backing

Xconomy

A team of decorated academic chemists in San Diego have been working since 2014 on a biotech startup that aims to find new drugs faster. The company now has a lot of cash in the bank and a well-known biopharma scientist to guide it.

Guide 10

Trump’s Election Stunner: Tech and Life Sciences Leaders React

Xconomy

” Xconomy’s editors contributed to this report. Still processing what this will mean for technology, business, society, and humanity—I guess it’s going to take a while. In the meantime, here are 10 notable reactions from around the Xconomy network, mostly via Twitter. As you might guess, they are a mix of outrage, resiliency, hope, rationalizing, grandstanding, and some calls for calm and reason (plus some calls to secede): 1.

Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More

Xconomy

The CRISPR news this week doesn’t need a metaphor; the drama that MIT Technology Review reported can stand alone. Waltham, MA-based Chiasma (NASDAQ: CHMA ) announced plans to slash 44 percent of its workforce… Portola Pharmaceuticals (NASDAQ: PTLA ) of South San Francisco, CA, said the FDA needs more information to make an approval decision about andexanet alfa (AndexXa), an emergency drug that reverses the effect of blood thinners.

Regulus Shares Crumble As FDA Halts Testing of Hepatitis C Drug

Xconomy

Regulus reported that a second serious case of jaundice, or a yellowing of the skin and eyes, in a Phase 1 study of RG-101. Regulus said it would report the trial results at future scientific meetings, but investors don’t seem interested in waiting patiently.

Study 15

Third-Quarter Report Shows Slowdown in VC Activity, & Top 10 Deals

Xconomy

Venture capital activity is gradually easing from last year’s peak, according to a new quarterly report put together by Seattle-based PitchBook and the National Venture Capital Association. deals (1,796 companies) during the third quarter that ended September 30, according to the inaugural “Venture Monitor” report released today. It was the fifth straight quarterly decline in the number of companies getting VC funding, according to the report. San Francisco, CA.

The Xconomy Immuno-Oncology Resource: A Mid-ASH T Cell Update

Xconomy

Xconomy reported last week on the new use of these cells to treat multiple myeloma.

Bio Roundup: RIP Roger Tsien, Novartis CAR-T Wheel, Zika News & More

Xconomy

Nobel Prize winner Roger Tsien, a UC San Diego chemist, passed away in Oregon this week. As the San Diego Union Tribune reported in 2013, Tsien (pictured) was also unafraid to shine the spotlight on what he considered suspect scientific approaches, even when espoused by legends like DNA co-discoverer James Watson. He was a professor at UC San Diego.

Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay

Xconomy

[ Editor’s note: Ben Fidler contributed to this report ] The week of frenetic data sharing, deal talking, and party hopping of the J.P. Morgan Janet Woodcock Jeff Marrazzo Jeff Mazzarro JJ Bienaime Joe Biden Johnson & Johnson JP Morgan JPM17 JPMorgan Julie Gerberding Life Sciences Maraganore Martin Shkreli Merck Novo Nordisk panel patient patisiran pay performance Poliwogg President elect Pricing rare disease San Francisco Sarepta Therapeutics Spark Therapetuics

Press 15

Pharma’s Productivity Problem: Finding More Blockbuster Drugs

Xconomy

A recent Silicon Valley Bank report noted that large corporations have dramatically increased pre-clinical acquisitions in the last three years under the pressure of limited supply and competition from IPOs. A recent Wall Street Journal article that raised the possibility of Biogen as the target of another huge pharma buyout cited the lack of productivity as a major driver of M&A in the pharmaceutical industry.